

# MabSelect Prisma

## AFFINITY CHROMATOGRAPHY

MabSelect™ Prisma is a next-generation Protein A chromatography resin that offers significantly enhanced alkaline stability and binding capacity for improved process economy in monoclonal antibody (mAb) processing. The resin builds on the proven track record of MabSelect and MabSelect SuRe™ resins in commercial mAb production. In comparison with its predecessors, however, MabSelect Prisma has been improved with an optimized high-flow agarose base matrix and a genetically engineered Protein A-derived ligand, allowing future demands in mAb processing to be met (Fig 1).

Key features of MabSelect Prisma include:

- Enhanced dynamic binding capacity (DBC) allows high mass throughput of processed mAb per resin volume unit.
- Excellent alkaline stability enables efficient cleaning and sanitization using 0.5–1.0 M NaOH for improved process economy and robustness.
- Covered by a comprehensive security of supply program, including dual sources of the agarose base matrix and Protein A ligand.

Since the first commercially approved mAb in 1980s, this class of therapeutic molecules has grown to represent a large part of biopharmaceutical sales. Today, mAbs represent the largest and fastest growing segment of biopharmaceuticals. Over the past 30 years, Protein A chromatography resins and mAbs have followed a highly synergistic evolutionary path, with annual productivity gains in the Protein A step of above 4.5% and increases in Protein A binding capacity of more than 5.5% (1).

With their high affinity for the antibody Fc region, Protein A resins provide an efficient mAb purification platform. The homology of the Fc region allows most of all mAbs to be purified using essentially the same standard approach, thereby significantly reducing process development time. This is an important factor, explaining why nearly all commercially approved mAb manufacturing processes utilize Protein A capture as the initial step in downstream purification. The main characteristics of MabSelect Prisma resin are summarized in Table 1.



**Fig 1.** MabSelect Prisma is developed to meet future demands in large-scale mAb processing.

## Designed for high productivity in mAb capture

Recent advances in upstream procedures are driving up the mass of mAb being sent to downstream purification, thus putting pressure on the Protein A step. With the increasing mAb titers, cell culture feed also contains increased levels of impurities. Concurrently, the high nutrient load present in the cell culture harvest, combined with a low alkaline resistance of the Protein A resin, results in an elevated risk of resin fouling and bioburden issues. For efficient purification of the upstream batch, the resin capacity needs to match the mass of produced mAb. Historically, binding capacity of Protein A resins has lagged behind ion exchange chromatography resins, resulting in the need for larger resin volumes and chromatography column sizes.

**Table 1.** Main characteristics of MabSelect PrismaA

|   |   |
|---|---|
| Matrix                                      | Highly cross-linked agarose, spherical  |
| Ligand                                      | Alkaline stabilized Protein A-derived ( <i>E. coli</i> )  |
| Ligand coupling                             | Single point attachment   |
| Coupling chemistry                          | Epoxy   |
| Particle size, $d_{50V}^*$                  | ~ 60 $\mu\text{m}$  |
| Dynamic binding capacity, $Q_{B10}^\dagger$ | ~ 80 mg human IgG/mL resin at 6 min residence time<br>~ 65 mg human IgG /mL resin at 4 min residence time |
| Recommended maximum operating flow velocity | 300 cm/h $^\ddagger$  |
| pH stability, operational $^\S$             | 3–12  |
| pH stability, CIP $^\ddagger$               | 2–14  |
| Chemical stability                          | Stable to commonly used aqueous buffers in Protein A chromatography.                                      |
| Delivery conditions                         | 20% ethanol<br>On request 2% benzyl alcohol (BnOH)  |

\* Median particle size of the cumulative volume distribution.


$^\dagger$  DBC at 10% breakthrough by frontal analysis at a mobile phase velocity of 100 cm/h (6 min residence time) and 150 cm/h (4 min residence time) in a lab column column at 10 cm bed height for human IgG in PBS buffer, pH 7.4.

$^\ddagger$  Packed in an AxiChrom™ 300 column with 30 cm i.d. at 20 cm bed height, using buffers with the same viscosity as water at 20°C.

$^\S$  pH range where resin can be operated without significant change in function.

$^\ddagger$  pH range where resin can be subjected to cleaning-in-place (CIP) without significant change in function.


Due to the enhanced properties of both the Protein A ligand and the base matrix design, MabSelect PrismaA offers significantly increased binding capacity compared with its predecessor, MabSelect SuRe LX resin (2). Figure 2 shows DBC of MabSelect PrismaA as compared with MabSelect SuRe and MabSelect SuRe LX resins at different residence times. Compared with MabSelect SuRe LX, the optimized base matrix of MabSelect PrismaA offers an up to 40% increase in DBC at a residence time of 2.4 min or up to 30% increased binding capacity at 4 min residence time. At 6 min residence time, a binding capacity of ~ 80 mg human IgG /mL resin was observed for MabSelect PrismaA, which is 25% higher than for MabSelect SuRe LX.




**Fig 2.** MabSelect PrismaA is developed to meet future demands in large-scale mAb processing.

For similar process setups and column sizes, the improved binding capacity of MabSelect PrismaA enables significantly increased mass throughput per purification cycle compared with MabSelect SuRe LX (Fig 3). With the increased binding capacity,

the productivity of current chromatography columns and systems can be improved without costly capital expenditures, making more efficient use of existing manufacturing footprint. Alternatively, the increased binding capacity can be used to decrease the resin volume (and concomitantly the buffer consumption) required to achieve a given mass throughput (Fig 4).



**Fig 3.** Example of the mass throughput increase enabled by using MabSelect PrismaA in comparison with MabSelect SuRe and MabSelect SuRe LX. Here, a fixed column size of 450/200 mm, a mAb titer of 4 g/L, and a 20% safety factor in loading were used.



**Fig 4.** Example of the resin volume savings enabled by using MabSelect PrismaA in comparison with MabSelect SuRe and MabSelect SuRe LX. Here, a safety factor of 20% was used in loading of a 2000 L bioreactor harvest with a mAb titer of 4 g/L.


## Consistent purification performance

Purification performance of MabSelect PrismA was investigated and found to be similar to its predecessors MabSelect SuRe LX and MabSelect SuRe resins (2). Performance was evaluated with regards to mAb recovery; removal of host cell protein (HCP), host cell DNA (hcDNA), and mAb aggregates; as well as Protein A ligand leakage (Fig 5–10). In addition, MabSelect PrismA exhibits a similar elution pH profile as MabSelect SuRe LX (not shown). Table 2 shows the load to each resin for the results presented in Figures 5–10.


Quantitation of protein A ligand leakage can be performed using the same commercial kits available for MabSelect SuRe and MabSelect SuRe LX.

**Table 2.** Load on columns


| Product           | Load mAb1 (g/L resin) | Load mAb2 (g/L resin) | Load mAb3 (g/L resin) |
|-------------------|-----------------------|-----------------------|-----------------------|
| MabSelect PrismA  | 58                    | 63                    | 51                    |
| MabSelect SuRe LX | 46                    | 43                    | 40                    |
| MabSelect SuRe    | 39                    | 36                    | 37                    |




**Fig 5.** Recovery (%) of (A) mAb1, (B) mAb2, and (C) mAb3.




**Fig 6.** Removal of HCP from (A) mAb1, (B) mAb2, and (C) mAb3. HCP concentration in loaded feed:  $1.4 \times 10^5$  for mAb1 and  $5.7 \times 10^5$  ppm for mAb2. Bar graphs show remaining HCP (ppm) in elution pool.




**Fig 7.** Removal of hcDNA from (A) mAb1, (B) mAb2, and (C) mAb3. DNA concentration in loaded feed: 8037 ppm mAb1 and 6785 ppm mAb2. Bar graphs show remaining hcDNA (ppm) in elution pool.



**Fig 8.** Aggregate removal from (A) mAb1, (B) mAb2, and (C) mAb3. Bar graphs show remaining mAb aggregates (%) in elution pool. The observed increased aggregate level is associated with the higher load.




**Fig 10.** Elution pool sizes from capture of (A) mAb1, (B) mAb2, and (C) mAb3.



**Fig 9.** Leached Protein A (ppm) in (A) mAb1, (B) mAb2, and (C) mAb3 elution pools. The slightly increased ligand levels observed with MabSelect PrismA is a result of the higher ligand density and higher ligand molecular weight for this resin compared with the predecessor MabSelect SuRe resins.

### MabSelect PrismA and binding to non-Fc regions

The binding of protein A mainly takes place between constant heavy chain domains,  $C_{H2}$  and  $C_{H3}$ , in the Fc region of the mAb (Fig 11). The protein A ligand in MabSelect PrismA has enhanced binding affinity for the  $V_{H3}$  sequence located on the variable heavy chain of the Fab region compared to its predecessors, MabSelect SuRe and MabSelect SuRe LX.



**Fig 11.** Different interaction points on mAb for alternative purification possibilities.

**Table 3.** Protein A binding amino acids in V<sub>H</sub>3 region of IgG antibodies. Table shows amino acids tolerated and amino acids not tolerated for binding according to literature

| V <sub>H</sub> 3 position | Tolerated            | Not tolerated   |
|---------------------------|----------------------|---|
| 15 (G)                    | G, D <sup>a</sup>    |   |
| 17 (S)                    | S, A <sup>a</sup>    |   |
| 19 (R)                    | R                    | K <sup>b</sup> , S <sup>b</sup> , A <sup>a</sup> , Q <sup>a</sup> |
| 57 (K/T)                  | K, R, T, P, S        | I, E, A <sup>b</sup>  |
| 59 (Y)                    | Y                    | V <sup>b</sup>  |
| 64 (K)                    | K, R, T, E           |   |
| 65 (G)                    | G                    | D, S <sup>c</sup>   |
| 66 (R)                    | R                    |   |
| 68 (T)                    | T, A <sup>b</sup>    | S <sup>b</sup>  |
| 70 (S)                    | S, T                 |   |
| 81 (Q)                    | Q                    | E <sup>c</sup>  |
| 82a (N)                   | N                    | D <sup>b</sup> , S <sup>b,c</sup> , A <sup>a</sup>                |
| 82b (S)                   | S, G, N <sup>b</sup> | D   |

a = Data from Fridy *et al.* Engineered high-affinity nanobodies recognizing staphylococcal Protein A and suitable for native isolation of protein complexes. *Anal. Biochem.* **477**, 92–94 (2015). <https://doi.org/10.1016/j.ab.2015.02.013>

b = Data from Henry *et al.* A rational engineering strategy for designing Protein A-binding Camelid single-domain antibodies. *PLoS ONE* **11**(9), 1–18 (2016). <https://doi.org/10.1371/journal.pone.0163113>

c = Data from Ollier *et al.* Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development. *mAbs* **11**(8), 1464–1478 (2019). <https://doi.org/10.1080/19420862.2019.1660564>

MabSelect, MabSelect SuRe, and MabSelect PrismaA interact to different degrees with V<sub>H</sub>H fragments. These V<sub>H</sub>H fragments are unique to Camelids and are single chain antibody mimics of the V<sub>H</sub>3 region of IgG, with mutations at different positions. The data in Table 4 shows different amino acid sequences of V<sub>H</sub>H fragments where mutations have been introduced in selected positions known to have high variability. The table demonstrates that MabSelect SuRe can interact with the V<sub>H</sub>3 region in some

**Table 4.** Interaction of MabSelect, MabSelect SuRe, and MabSelect PrismaA with V<sub>H</sub>H fragments

| V <sub>H</sub> H sequence | MabSelect | MabSelect SuRe | MabSelect PrismaA |
|---------------------------|-----------|----------------|-------------------|
| T57                       | Yes       | Yes            | Yes               |
| T57K                      | Yes       | No             | Yes               |
| T57I                      | No        | No             | No                |
| T57E                      | No        | No             | No                |
| N82aT, S82bD              | No        | No             | No                |
| T57P                      | Yes       | No             | Yes               |
| T57S                      | Yes       | No             | Yes               |
| T57R                      | Yes       | No             | Yes               |
| K64R                      | Yes       | Yes            | Yes               |
| K64T                      | Yes       | Yes            | Yes               |
| K64E                      | Yes       | N/A            | Yes               |
| G65D                      | No        | No             | No                |
| S70T                      | Yes       | No             | Yes               |
| S82bD                     | No        | No             | No                |
| S82bG                     | Yes       | Yes            | Yes               |

cases, but MabSelect and MabSelect PrismaA are less sensitive to sequence variation. The results also show that MabSelect PrismaA has a similar binding pattern for the tested V<sub>H</sub>H sequences as the recombinant protein A ligand present in MabSelect and MabSelect Xtra™ resins, which provides new opportunities for purification of increasing molecular diversity of antibody fragments.

### Purification performance of antibody fragments

The binding capacity for V<sub>H</sub>H was determined by frontal analysis and elution pH using a pH gradient from pH 6 to pH 3 on MabSelect PrismaA (Table 5).

**Table 5.** Binding capacity and elution pH of a V<sub>H</sub>H fragment using MabSelect PrismaA

| Entity           | Q <sub>B10</sub> (g/L) | Q <sub>B10</sub> (mM) | Elution pH |
|------------------|------------------------|-----------------------|------------|
| V <sub>H</sub> H | 42                     | 2.7                   | 3.8        |

A 150 mL volume of clarified *E. coli* harvest containing 0.2 g/L VHH (30 g of V<sub>H</sub>H/L resin) was loaded at 6 min residence time to a MabSelect PrismaA column (CV 1 mL). The V<sub>H</sub>H fragment was eluted in 50 mM sodium acetate, pH 3.5. Results showed that a 4.3 log<sub>10</sub> reduction of HCP was achieved. The leached protein A ligand concentration was 10 ppm (Table 6).


**Table 6.** HCP and leached protein A ligand concentration in the purification of a V<sub>H</sub>H fragment from *E. coli* on MabSelect PrismaA resin

| Sample       | Pool volume (CV) | eHCP (ppm*) | Leached ligand (ppm†) |
|--------------|------------------|-------------|-----------------------|
| Load         | NA               | 4 252 500   | NA                    |
| Elution pool | 1                | 200         | 10                    |

\* Nanogram (ng) of eHCP/mg V<sub>H</sub>H  
† ng of leached ligand/mg V<sub>H</sub>H

## Rigid, highly cross-linked agarose base matrix allows for high flow velocities

MabSelect PrismA features a highly cross-linked agarose base matrix that allows for high flow velocities in process-scale operations. This permits high-throughput purification of mAbs and other antibody molecules from large feed volumes. Figure 12 shows pressure-flow curves for MabSelect PrismA, enabling flow velocities as high as 300 cm/h, as verified in large BioProcess™ columns. For more information on packing MabSelect PrismA in large-scale columns, see reference 3.



**Fig 12.** Pressure-flow curve for MabSelect PrismA packed in a AxiChrom 300 column to a 20 cm bed height, generated at a temperature of 20°C. Recommended maximum operating flow velocity is 300 cm/h.


## Improved alkaline stability enables new standards for cleaning and sanitization

Due to its efficacy, low cost, as well as ease of detection, removal, and disposal, sodium hydroxide (NaOH) has gained popularity for cleaning and sanitization in the bioprocessing industry. Commonly, 1 M NaOH is used for cleaning and sanitization of chromatography columns and resins. Apart from its ability to inactivate endotoxins and many microorganisms, NaOH can remove bound proteins, nucleic acids, and lipids from the resins. Fouled resins can increase cross-contamination risk and also negatively impact DBC over time (4).

Historically, Protein A chromatography resins have been sensitive to NaOH due to the limited alkaline stability of the protein ligand. Later generations of Protein A resins exhibit improved alkaline stability and have recommended cleaning procedures using 0.1 M NaOH, with the option of occasional use of 0.5 M NaOH. Given that Protein A capture is the first purification step and therefore exposed to the crudest feed and highest impurity loads, the use of weak CIP agents has been highlighted as a challenge and risk with using this technique.

With enhanced alkaline stability of its Protein A ligand, MabSelect PrismA meets this challenge (5). The ligand was developed using high-throughput screening to identify amino acids sensitive to alkaline degradation and substitution of these amino acids with more stable ones. The final construct constitutes a hexamer of the engineered domain. Highly pure ligand is immobilized to the agarose base matrix via a chemically stable thioether linkage. The enhanced alkaline stability enables efficient cleaning of the resin using 0.5 to 1.0 M NaOH over many purification cycles.

Figure 13 shows relative remaining DBC of MabSelect PrismA as compared with MabSelect SuRe and MabSelect SuRe LX over repeated CIP cycles. As shown, MabSelect PrismA retains more than 90% of its initial DBC after more than 150 cycles with 1.0 M NaOH, while only 50% of the initial DBC of MabSelect SuRe LX remains after an equivalent number of CIP cycles. Using 0.5 M NaOH, MabSelect PrismA retains more than 93% of its initial DBC after 300 cycles (6).




**Fig 13.** Relative remaining DBC using (A) 0.5 M NaOH and (B) 1.0 M NaOH as cleaning agent at 15 min contact time between cycles.



## Addressing spore-forming bacteria for improved bioburden control

The increased alkaline stability helps maintain bioburden growth control as well as decrease process-deviation risks and associated costs. Advancements in the design of sanitization methods have resulted in efficient removal also of spore-forming bacteria. Studies have shown that the oxidizing agent peracetic acid (PAA) is highly efficient in reducing bacterial spores (5). A more than  $6.0 \log_{10}$  reduction of *Bacillus subtilis* spores was obtained already after a 15 min treatment with 30 mM PAA or after a 30 min treatment with 20 mM PAA (Fig 14).

PAA is a strong oxidizing agent that might be expected to have a negative impact on the performance of chromatography resins, in particular those containing protein ligands. However, studies indicate that PAA at limited contact (2 to 3 times during the lifetime of the MabSelect SuRe resin) can provide a good safeguard against spore-forming bacteria, without negatively impacting resin performance or lifetime (7). Studies are on-going to develop a similar recommendation for MabSelect Prisma.



**Fig 14.** *B. subtilis* spore challenge test in a 50% MabSelect SuRe resin slurry, showing sporicidal effects of 30 and 20 mM PAA already at 15 to 30 min contact time.


## Proven technology for seamless scale-up

Protein A affinity chromatography is an established method for fast and low-risk capture of mAb molecules. The method is scalable from microliter levels to tens of thousands of liters of cell culture feed. Defined conditions for loading, wash, elution, and CIP can be verified and optimized using small prepacked HiScreen™ columns (4.7 mL). Together with a chromatography system, such as ÄKTA™ avant or ÄKTA pure, the HiScreen column format helps develop an efficient and robust separation method. Further development and optimization for process scale-up can be conducted using the well-established user-packed AxiChrom or prepacked ReadyToProcess™ columns.

### Adds flexibility to production

MabSelect Prisma prepacked in ReadyToProcess columns provides sufficient capacity for purification of mAbs even from large quantities of cell culture feed (Fig 15). With a DBC reaching 80 mg/mL, MabSelect Prisma prepacked in the ReadyToProcess 57 L (600/200 mm) column enables processing of high-titer bioreactor harvests of up to 2000 L in a single working day. The disposable ReadyToProcess columns offer the benefits of single-use technology with regard to fast setup, reduced cross-contamination risk, and high flexibility for quick adaption of production scales to market needs.

For reuse columns, the high productivity of MabSelect Prisma offers a reduced facility footprint and processing time. The enhanced alkaline stability of MabSelect Prisma also provides opportunities for mAb processing using continuous chromatography, where the extended exposure to high impurity loads causes increased risks of bioburden growth. The high alkaline stability of the resin allows for significantly improved control of both cleaning and sanitization under the more challenging conditions of continuous chromatography setups.



**Fig 15.** The enhanced binding capacity of MabSelect Prisma enables use of smaller columns. Prepacked ReadyToProcess columns support mAb purification from high-titer bioreactor harvests of up to 2000 L.

## Supply chain stability

The complex nature of biopharmaceuticals makes manufacturing a challenge, in which a consistent, high-quality end product is depending on the use of equally consistent, high-quality manufacturing components. Cytiva has made significant investments in supply stability to ensure security of supply of MabSelect Prisma. For critical raw materials, such as the Protein A ligand and the agarose base matrix, dual sourcing has been validated and implemented. Protein A ligand production has been partially in-sourced to ensure supply security (the remaining ligand is produced by a contract manufacturer using our developed process).

For emergency preparedness, large investments have been made and efforts implemented to minimize risk and impact of supply interruptions in our manufacturing. Cytiva's chromatography product manufacturing has been certified to ISO22301 business continuity management. As an extra precaution in the event of a disruption of our supply chain, a strategic reserve of chromatography resins used in approved manufacturing processes has been created to ensure coverage during the recovery phase (8).

### BioProcess resin support

MabSelect Prisma belongs to the BioProcess family of products that is developed and supported for large-scale manufacture of biopharmaceuticals. This support includes validated manufacturing methods, secure long-term resin supply, and regulatory support files (RSF) to assist process validation and submission to regulatory authorities. In addition, Fast Trak training and education provide high-level, hands-on training in all key aspects of process development and manufacturing.

## Resin storage

Store unused MabSelect Prisma in its container at a temperature of 2°C to 8°C. Ensure that the screw top is fully tightened. Equilibrate packed columns in buffer containing 20% ethanol or 2% BnOH.

After storage, equilibrate with starting buffer and perform a blank run, including CIP, before use. In case of bioburden incidents, treatment with PAA can be performed to reduce spore-forming bacteria.

## References

1. Bolton G. R. and Mehta, K. K. The role of more than 40 years of improvement in Protein A chromatography in the growth of the therapeutic antibody industry. *Biotechnol. Prog.* **32**, 1193–1202 (2016). <https://doi.org/10.1002/btpr.2324>
2. Application note: Capacity and performance of MabSelect Prisma protein A chromatography resin. GE Healthcare, KA1965231408AN (2018).
3. Article: Verified chromatography column packing methods for MabSelect Prisma resin.
4. Zhang J. *et al.* Maximizing the functional lifetime of Protein A resins. *Biotechnol. Prog.* **33**, 708–715 (2017). <https://doi.org/10.1002/btpr.2448>
5. Whitepaper: Efficient cleaning-in-place methods for protein-based antibody affinity chromatography resins. Cytiva. KA1619220218WP (2018).
6. Application note: Lifetime performance study of MabSelect Prisma during repeated cleaning-in-place cycles. GE Healthcare, KA1061080618AN (2018).
7. Application note: Impact of sporicidal agent on MabSelect SuRe Protein A resin lifetime. GE Healthcare, 29262168, Edition AA (2017).
8. Whitepaper: Security of supply for chromatography media. GE Healthcare, 29085383, Edition AA (2014).



## Ordering information

| <b>Product</b>                             | <b>Size</b>            | <b>Product code</b> |
|--|------------------------|---------------------|
| MabSelect PrismA                           | 25 mL                  | 17549801            |
| MabSelect PrismA                           | 200 mL                 | 17549802            |
| MabSelect PrismA                           | 1 L                    | 17549803            |
| MabSelect PrismA                           | 5 L                    | 17549804            |
| MabSelect PrismA                           | 10 L (made to order)   | 17549805            |
| MabSelect PrismA in BnOH                   | 1 L (made to order)    | 17549823            |
| MabSelect PrismA in BnOH                   | 5 L (made to order)    | 17549824            |
| MabSelect PrismA in BnOH                   | 10 L (made to order)   | 17549825            |
| HiTrap™ MabSelect PrismA                   | 1 × 1 mL               | 17549851            |
| HiTrap MabSelect PrismA                    | 5 × 1 mL               | 17549852            |
| HiTrap MabSelect PrismA                    | 1 × 5 mL               | 17549853            |
| HiTrap MabSelect PrismA                    | 5 × 5 mL               | 17549854            |
| HiScreen MabSelect PrismA                  | 1 × 4.7 mL             | 17549815            |
| PreDicator™ MabSelect PrismA               | 6 µL                   | 17549830            |
| PreDicator MabSelect PrismA                | 20 µL                  | 17549831            |
| PreDicator MabSelect PrismA                | 50 µL                  | 17549832            |
| PreDicator RoboColumn™<br>MabSelect PrismA | 200 µL                 | 17549833            |
| PreDicator RoboColumn<br>MabSelect PrismA  | 600 µL                 | 17549834            |
| ReadyToProcess MabSelect PrismA            | column 1.0 L (80/200)  | 17549861            |
| ReadyToProcess MabSelect PrismA            | column 2.5 L (126/200) | 17549862            |

## Related literature

| <b>Data files</b>  | <b>Product code</b> |
|--------------------|---------------------|
| MabSelect          | 18114994            |
| MabSelect Xtra     | 11001157            |
| MabSelect SuRe     | 11001165            |
| MabSelect SuRe LX  | 28987062            |
| MabSelect SuRe pcc | 28987062            |

## **cytiva.com/bioprocess**

For local office contact information, visit [cytiva.com/contact](https://cytiva.com/contact)

Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate. ÄKTA, AxiChrom, BioProcess, HiScreen, HiTrap, MabSelect, MabSelect Xtra, MabSelect SuRe, PreDictor, and ReadyToProcess are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

RoboColumn is a trademark of Repligen GmbH. GE and the GE Monogram are trademarks of General Electric Company. All other third-party trademarks are the property of their respective owners.

© 2020 Cytiva

All goods and services are sold subject to the terms and conditions of sale of the supplying company operating within the Cytiva business. A copy of those terms and conditions is available on request. Contact your local Cytiva representative for the most current information.

CY553-17Sep20-DF

